Your browser doesn't support javascript.
loading
Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine.
Galaine, Jeanne; Borg, Christophe; Godet, Yann; Adotévi, Olivier.
Afiliação
  • Galaine J; INSERM UMR1098, Besançon cedex F25020, France. jeanne.galaine@edu.univ-fcomte.fr.
  • Borg C; Université de Franche-Comté, Besançon cedex F25020, France. jeanne.galaine@edu.univ-fcomte.fr.
  • Godet Y; EFS Bourgogne Franche-Comté, Besançon cedex F25020, France. jeanne.galaine@edu.univ-fcomte.fr.
  • Adotévi O; INSERM UMR1098, Besançon cedex F25020, France. christophe.borg@efs.sante.fr.
Vaccines (Basel) ; 3(3): 490-502, 2015 Jun 30.
Article em En | MEDLINE | ID: mdl-26350591
Nowadays, immunotherapy represents one promising approach for cancer treatment. Recently, spectacular results of cancer immunotherapy clinical trials have confirmed the crucial role of immune system in cancer regression. Therapeutic cancer vaccine represents one widely used immunotherapy strategy to stimulate tumor specific T cell responses but clinical impact remains disappointing in targeting CD8 T cells. Although CD8 T cells have been initially considered to be the main protagonists, it is now clear that CD4 T cells also play a critical role in antitumor response. In this article, we discuss the role of tumor antigen-specific CD4 T cell responses and how we can target these cells to improve cancer vaccines.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2015 Tipo de documento: Article